Kidney Cancer

Patients with advanced renal cell carcinoma may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib).

“I’m not going to give up on that just because of this pandemic. Health is most important, as it should be for us cancer survivors.”

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

“I thought, you know what I have control right now: if I'm going to laugh, if I'm going to enjoy my family, or if I'm going to hide in a corner and cry all day. I'm not going to do that. I'm not going to let cancer do that to me.”

Once a patient progresses following initial treatment for kidney cancer, one expert says TKIs are the next step in therapy.

Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.

The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.

Young Investigator and Advanced Discovery Awards will advance kidney cancer research, as the Kidney Cancer Association opens up its grant applications.

African American race was associated with longer survival in non-clear cell metastatic renal cell carcinoma compared with Hispanic and Caucasian patients.

From New Jersey Governor Phil Murphy announcing he will undergo surgery to remove a potentially cancerous tumor on his kidney to an NHL team granting a 15-year-old fan with cancer the ultimate wish, here’s what is making headlines in the cancer space this week.

Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.

Here’s a look at what’s inside our 2020 Winter issue.

Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.

The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.

Findings from a recent study supported further evaluation of comparing anti–PD-1 to anti–PD-L1 therapy to help determine treatment options for patients with cancer.

Personalized treatments have changed the cancer landscape, and continue to change it for patients with renal cell carcinoma.

A physician’s social network is important to determining the adoption of high-value cancer drugs, as researchers have determined peer influence had a strong association with the adoption of Avastin among oncologists across the nation.

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

A phase 3 clinical trial investigating Fotivda improved chances of preventing disease progression in patients with kidney cancer compared with Nexavar.